Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Eagle Pharmaceuticals (EGRX)

Eagle Pharmaceuticals (EGRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 58,182
  • Shares Outstanding, K 12,987
  • Annual Sales, $ 316,610 K
  • Annual Income, $ 35,640 K
  • 60-Month Beta 0.41
  • Price/Sales 0.23
  • Price/Cash Flow 1.24
  • Price/Book 0.24
Trade EGRX with:

Options Overview Details

View History
  • Implied Volatility 154.16% ( +16.55%)
  • Historical Volatility 82.57%
  • IV Percentile 87%
  • IV Rank 59.20%
  • IV High 245.66% on 04/05/24
  • IV Low 21.43% on 10/16/23
  • Put/Call Vol Ratio 1.25
  • Today's Volume 9
  • Volume Avg (30-Day) 35
  • Put/Call OI Ratio 1.83
  • Today's Open Interest 1,105
  • Open Int (30-Day) 1,013

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.28 +7.71%
on 04/15/24
5.82 -20.79%
on 03/21/24
-0.89 (-16.18%)
since 03/19/24
3-Month
4.28 +7.71%
on 04/15/24
6.81 -32.31%
on 03/01/24
+0.13 (+2.90%)
since 01/19/24
52-Week
4.10 +12.44%
on 01/16/24
30.40 -84.84%
on 05/09/23
-23.79 (-83.77%)
since 04/19/23

Most Recent Stories

More News
Eagle Pharmaceuticals: Q2 Earnings Snapshot

Eagle Pharmaceuticals: Q2 Earnings Snapshot

EGRX : 4.61 (+2.90%)
Eagle Pharmaceuticals (EGRX) Q1 Earnings and Revenues Beat Estimates

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 5.88% and 3.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

EGRX : 4.61 (+2.90%)
SMFL : 0.4810 (+4.00%)
Eagle Pharmaceuticals: Q1 Earnings Snapshot

Eagle Pharmaceuticals: Q1 Earnings Snapshot

EGRX : 4.61 (+2.90%)
Maravai LifeSciences Holdings, Inc. (MRVI) Lags Q1 Earnings and Revenue Estimates

Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of -25% and 0.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the...

MRVI : 7.30 (-4.07%)
EGRX : 4.61 (+2.90%)
Chimerix (CMRX) Reports Q1 Loss, Misses Revenue Estimates

Chimerix (CMRX) delivered earnings and revenue surprises of 0% and 19.14%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

CMRX : 0.8844 (-5.14%)
EGRX : 4.61 (+2.90%)
Eagle Pharmaceuticals (EGRX) Beats Q4 Earnings and Revenue Estimates

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 41.03% and 2.90%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

EGRX : 4.61 (+2.90%)
IMCC : 0.6075 (+2.97%)
Eagle Pharmaceuticals: Q4 Earnings Snapshot

Eagle Pharmaceuticals: Q4 Earnings Snapshot

EGRX : 4.61 (+2.90%)
Should Value Investors Buy Eagle Pharmaceuticals (EGRX) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

EGRX : 4.61 (+2.90%)
Are Investors Undervaluing Eagle Pharmaceuticals (EGRX) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

EGRX : 4.61 (+2.90%)
QDEL : 39.12 (+2.25%)
Eagle Pharmaceuticals (EGRX) Q3 Earnings and Revenues Beat Estimates

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 33.33% and 11.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

EGRX : 4.61 (+2.90%)
ACB : 6.46 (-1.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102,...

See More

Key Turning Points

3rd Resistance Point 5.09
2nd Resistance Point 4.92
1st Resistance Point 4.70
Last Price 4.61
1st Support Level 4.31
2nd Support Level 4.14
3rd Support Level 3.92

See More

52-Week High 30.40
Fibonacci 61.8% 20.35
Fibonacci 50% 17.25
Fibonacci 38.2% 14.15
Last Price 4.61
52-Week Low 4.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar